The PARP Inhibitor Family
Nicotinamide Mimic Inhibitors — NAD+ Competitive Binding and BRCA Synthetic Lethality SAR
## Overview
PARP inhibitors represent one of the most compelling examples of the synthetic lethality concept translated into clinical oncology. Poly(ADP-ribose) polymerase 1 and 2 (PARP1/2) are nuclear enzymes that detect single-strand DNA breaks (SSBs) and orchestrate base excision repair (BER) by adding poly(ADP-ribose) (PAR) chains to chromatin proteins and recruiting repair factors. PARP inhibitors block this activity, causing SSBs to persist and collapse into double-strand breaks (DSBs) at replication forks. In cells with intact homologous recombination (HR), DSBs are efficiently repaired. In BRCA1/2-mutated cells lacking functional HR, DSBs accumulate, causing catastrophic genomic instability and cell death—exploiting the "synthetic lethality" between PARP inhibition and HR deficiency.
## Nicotinamide Bioisostere Pharmacophore
PARP inhibitors are competitive inhibitors of the NAD+ substrate at PARP1/2's catalytic (CAT) domain. The catalytic site has a shallow "NAD-binding" D-loop that normally binds the nicotinamide portion of NAD+. The nicotinamide amide makes two critical H-bonds: the NH donates to Gly863 backbone carbonyl, and the carbonyl accepts from Ser904 hydroxyl. PARP inhibitors mimic this bidentate interaction using bioisosteric pharmacophores: benzamide (veliparib), phthalazinone (olaparib), 2,3-dihydro-1,4-dioxino[2,3-g]isoquinolin-6(5H)-one (rucaparib), or indazole-4-carboxamide (niraparib). All share the essential NH-C=O group positioned to make these two H-bonds.
## PARP Trapping: Beyond Catalytic Inhibition
A critical insight distinguishing clinical PARP inhibitors is "PARP trapping"—the ability to stabilize covalent PARP1-DNA complexes on damaged DNA. Trapped PARP-DNA complexes are cytotoxic by physically blocking replication forks and interfering with repair factor recruitment. Trapping potency is distinct from catalytic inhibition: veliparib is a potent catalytic inhibitor (IC50 ~5 nM) but a weak trapper; olaparib inhibits with similar IC50 but traps ~100-fold more PARP-DNA complexes per molecule of inhibitor. The phthalazinone scaffold in olaparib induces conformational changes in PARP1's N-terminal zinc finger domains and WGR domain that tighten PARP1-DNA binding. Clinical data suggest trapping potency correlates with single-agent efficacy: olaparib, niraparib, and rucaparib (moderate-high trappers) show better single-agent responses than veliparib (weak trapper), which requires chemotherapy combination.
## Synthetic Lethality and BRCA1/2 Biology
BRCA1 and BRCA2 are HR pathway tumor suppressors. BRCA2 directly loads RAD51 onto ssDNA at DSBs to initiate strand invasion and HR. BRCA1 coordinates 5' end resection and RAD51 loading. In BRCA-mutated tumors, HR is non-functional; DSBs formed by replication fork collapse at PARP-trapped SSBs cannot be repaired, leading to mitotic catastrophe. Approximately 15% of ovarian cancers and 5–7% of breast cancers carry germline BRCA1/2 mutations. Somatic BRCA1/2 mutations and epigenetic silencing expand the HRD-positive population to ~50% of high-grade serous ovarian cancers.
## Approved Agents and Clinical Indications
**Olaparib** (Lynparza, 2014): first approved PARP inhibitor; indicated for BRCA1/2-mutated ovarian, breast, pancreatic, and prostate cancers. **Rucaparib** (Rubraca, 2016): pyrrolocarboxamide scaffold; BRCA-mutated ovarian cancer. **Niraparib** (Zejula, 2017): unique in lacking BRCA requirement for ovarian cancer maintenance (HRD-positive selection); piperidinyl-indazole scaffold; once-daily oral. **Talazoparib** (Talzenna, 2018): most potent PARP trapper in the class (>30-fold more trapping than olaparib); phthalazinone-based; BRCA-mutated HER2-negative breast cancer.
## Resistance Mechanisms
Primary resistance: loss of PARP1 expression/mutation (reduces trapping target); secondary resistance: restoration of HR via BRCA1/2 reversion mutations (most common, ~50% of resistant ovarian cancers), RAD51 overexpression, or stabilization of replication forks via 53BP1 loss. Understanding resistance patterns has driven combination strategies: PARP inhibitors + ATR inhibitors (synergistic in BRCA-revertant models), PARP inhibitors + anti-angiogenics (bevacizumab + olaparib first-line), PARP inhibitors + anti-VEGF/PI3K pathway inhibitors.
## Key Takeaways
- The nicotinamide-mimicking amide NH-C=O is the essential pharmacophore making bidentate H-bonds to PARP1 NAD+ site (Gly863, Ser904)
- PARP trapping (PARP-DNA complex stabilization) is mechanistically and clinically distinct from catalytic inhibition; phthalazinone/pyrrolocarboxamide scaffolds are superior trappers
- Synthetic lethality with BRCA1/2 deficiency is the primary mechanism: trapped PARP-DNA complexes at SSBs collapse into DSBs that HR-deficient cells cannot repair
- HRD biomarkers (genomic scarring) expand patient selection beyond BRCA-mutation carriers to ~50% of high-grade serous ovarian cancer
- BRCA reversion mutations are the dominant acquired resistance mechanism, driving combination therapy development to restore PARP inhibitor sensitivity
YAİ Özeti
Key SAR findings for the PARP inhibitor family:
- The benzamide (or phthalazinone) pharmacophore is a nicotinamide bioisostere that makes the critical bidentate H-bond pair to Gly863 and Ser904 of the PARP1 NAD+ binding site (the same contacts made by NAD+'s nicotinamide amide).
- The amide NH of the nicotinamide mimic is essential: NH→O substitution or N-methylation abolishes PARP1 inhibition; this NH donates to Gly863 backbone carbonyl.
- "Trapping" potency (PARP-DNA complex stabilization) is distinct from catalytic inhibition: olaparib > rucaparib > niraparib > veliparib in trapping potency; veliparib inhibits catalysis but poorly traps, explaining its weaker single-agent efficacy.
- Trapping arises from inhibitor-induced conformational changes in the PARP1 N-terminal regulatory domain (WGR domain) that stabilize PARP1-DNA binding; phthalazinone and pyrrolocarboxamide scaffolds achieve stronger trapping vs benzamide alone.
- BRCA1/2 mutation is the primary predictive biomarker because PARP1 trapping on unrepaired SSBs causes DSBs at replication forks, which BRCA-deficient cells cannot repair via homologous recombination.
- "HRD" (homologous recombination deficiency) score biomarkers (genomic scarring: LOH, LST, TAI) expand the biomarker-selected population beyond BRCA1/2 mutation carriers to include sporadic HR-deficient tumors.